文献速递泌尿男性生殖肿瘤

自体树突状细胞免疫治疗联合多西他赛与泼尼松对比安慰剂治疗转移性去势抵抗性前列腺癌的疗效与安全性:VIABLE 3期随机临床试验

Efficacy and Safety of Autologous Dendritic Cell-Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer: The VIABLE Phase 3 Randomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2022-01-01

VIABLE为双盲、平行分组、安慰剂对照3期随机试验,2014年6月至2017年11月在美国和欧洲177家医院诊所纳入1182例转移性去势抵抗性前列腺癌患者,按2:1随机接受DCVAC/PCa或安慰剂联合多西他赛加泼尼松。DCVAC/PCa组与安慰剂组总生存无差异(中位23.9个月 vs 24.3个月;HR 1.04;95%CI 0.90-1.21;P=0.60),次要疗效终点亦无差异,耐受性良好。

要点

  • DCVAC/PCa联合多西他赛加泼尼松未延长mCRPC患者总生存(HR 1.04;95%CI 0.90-1.21;P=0.60)。
  • DCVAC/PCa组与安慰剂组影像学无进展生存、PSA进展时间及骨相关事件均无差异。
  • DCVAC/PCa或安慰剂相关治疗中出现的不良事件分别为69/749(9.2%)和48/379(12.7%)。

核心结论

  • 在mCRPC患者中,DCVAC/PCa联合多西他赛加泼尼松并继续维持治疗未延长总生存,且耐受性良好。

研究设计与样本

  • VIABLE为双盲、平行分组、安慰剂对照3期随机临床试验,2014年6月至2017年11月在美国和欧洲177家医院诊所纳入mCRPC患者。
  • 共1182例男性mCRPC患者(中位年龄68岁,范围46-89岁)按2:1随机接受DCVAC/PCa(n=787)或安慰剂(n=395)。
  • 分层因素为地理区域(美国或非美国)、既往治疗(阿比特龙、恩扎卢胺或均无)和东部肿瘤协作组体能状态(0-1或2)。
  • DCVAC/PCa或安慰剂皮下给药,每3至4周一次,最多15剂。
  • 数据分析于2019年12月至2020年7月进行。

主要发现

  • 全部随机患者中DCVAC/PCa组与安慰剂组总生存无差异(中位23.9个月[95%CI 21.6-25.3] vs 24.3个月[95%CI 22.6-26.0];HR 1.04;95%CI 0.90-1.21;P=0.60)。
  • 次要疗效终点(影像学无进展生存、前列腺特异性抗原进展时间或骨相关事件)均无差异。
  • DCVAC/PCa或安慰剂相关治疗中出现的不良事件分别发生于69/749(9.2%)和48/379(12.7%)例患者。
  • DCVAC/PCa组(n=749)与安慰剂组(n=379)最常见的治疗中出现的不良事件为疲乏(271[36.2%] vs 152[40.1%])、脱发(222[29.6%] vs 130[34.3%])和腹泻(206[27.5%] vs 117[30.9%])。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: DCVAC/PCa is an active cellular immunotherapy designed to initiate an immune response against prostate cancer. OBJECTIVE: To evaluate the efficacy and safety of DCVAC/PCa plus chemotherapy followed by DCVAC/PCa maintenance treatment in patients with metastatic castration-resistant prostate cancer (mCRPC). DESIGN, SETTING, AND PARTICIPANTS: The VIABLE double-blind, parallel-group, placebo-controlled, phase 3 randomized clinical trial enrolled patients with mCRPC among 177 hospital clinics in the US and Europe between June 2014 and November 2017. Data analyses were performed from December 2019 to July 2020. INTERVENTIONS: Eligible patients were randomized (2:1) to receive DCVAC/PCa (add-on and maintenance) or placebo, both in combination with chemotherapy (docetaxel plus prednisone). The stratification was applied according to geographical region (US or non-US), prior therapy (abiraterone, enzalutamide, or neither), and Eastern Cooperative Oncology Group performance status (0-1 or 2). DCVAC/PCa or placebo was administered subcutaneously every 3 to 4 weeks (up to 15 doses). MAIN OUTCOMES AND MEASURES: The primary outcome was overall survival (OS), defined as the time from randomization until death due to any cause, in all randomized patients. Survival was compared using 2-sided log-rank test stratified by geographical region, prior therapy with abiraterone and/or enzalutamide, and Eastern Cooperative Oncology Group performance status. RESULTS: A total of 1182 men with mCRPC (median [range] age, 68 [46-89] years) were randomized to receive DCVAC/PCa (n = 787) or placebo (n = 395). Of these, 610 (81.8%) started DCVAC/PCa, and 376 (98.4%) started placebo. There was no difference in OS between the DCVAC/PCa and placebo groups in all randomized patients (median OS, 23.9 months [95% CI, 21.6-25.3] vs 24.3 months [95% CI, 22.6-26.0]; hazard ratio, 1.04; 95% CI, 0.90-1.21; P = .60). No differences in the secondary efficacy end points (radiological progression-free survival, time to prostate-specific antigen progression, or skeletal-related events) were observed. Treatment-emergent adverse events related to DCVAC/PCa or placebo occurred in 69 of 749 (9.2%) and 48 of 379 (12.7%) patients, respectively. The most common treatment-emergent adverse events (DCVAC/PCa [n = 749] vs placebo [n = 379]) were fatigue (271 [36.2%] vs 152 [40.1%]), alopecia (222 [29.6%] vs 130 [34.3%]), and diarrhea (206 [27.5%] vs 117 [30.9%]). CONCLUSIONS AND RELEVANCE: In this phase 3 randomized clinical trial, DCVAC/PCa combined with docetaxel plus prednisone and continued as maintenance treatment did not extend OS in patients with mCRPC and was well tolerated. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02111577.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Vogelzang NJ, Beer TM, Gerritsen W, et al. Efficacy and Safety of Autologous Dendritic Cell-Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer: The VIABLE Phase 3 Randomized Clinical Trial. JAMA Oncol. 2022. PMID: 35142815. doi:10.1001/jamaoncol.2021.7298

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。